Table 1 Patient characteristics
Characteristics | n (%)/mean [min–max] |
|---|---|
Age | 71 [61–88] |
Pretherapeutic PSA value [ng/ml] | 591 [14–3277] |
Pretherapeutic ECOG PSa | |
 0 | 7 (29.2%) |
 1 | 16 (66.7%) |
 2 | 1 (4.2%) |
Previous treatments | |
 Prostatectomy | 11 (45.8%) |
 Radiation | 15 (62.5%) |
 Androgen deprivation therapy | 24 (100%) |
 Enzalutamide or abiraterone | 23 (95.8%) |
  Enzalutamide | 20 (83.3%) |
  Abiraterone | 22 (91.7%) |
  Enzalutamide and abiraterone | 19 (79.2%) |
 Chemotherapy | 19 (79.2%) |
  Docetaxel | 19 (79.2%) |
  Cabazitaxel | 8 (33.3%) |
  Docetaxel and cabazitaxel | 8 (33.3%) |
 223Ra therapy | 8 (33.3%) |
 153Sm therapy | 1 (4.2%) |
Sites of metastases | |
 Bone | 24 (100%) |
 Lymph node | 18 (75%) |
 Other | 10 (41.7%) |
Tumor load according to [25] | |
 High | 11 (45.8%) |
 Medium | 13 (54.2%) |
 Low | 0 (0 %) |